Login to Your Account

PDL, Roche: Potential $205M Zenapax Deal Targets Asthma

By Randall Osborne

Friday, September 17, 2004
About a year after regaining from F. Hoffman-La Roche Inc. the rights to Zenapax (daclizumab) in all rights except transplant rejection, Protein Design Labs Inc. signed a potential $205 million deal for Roche to co-develop and sell the Phase II compound for asthma and related respiratory diseases. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription